In this context, we performed preclinical studies on BL and PTLD xenograft mouse models aimed at determining the therapeutic potential of inhibiting BCL‐2, either as a monotherapy or as a sensitizing factor for conventional treatments of B lymphoproliferative disorders associated with EBV. This evidence concerns the gene BCL2 and post-transplant lymphoproliferative disease.